Guangzhou Virotech Pharmaceutical Co., Ltd.
7
5
5
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 7 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma
Role: lead
A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors
Role: lead
A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer
Role: collaborator
A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors
Role: lead
A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors
Role: lead
A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic Cancer
Role: collaborator
IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC
Role: collaborator
All 7 trials loaded